Compare VTMX & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTMX | PBLS |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2023 | 2026 |
| Metric | VTMX | PBLS |
|---|---|---|
| Price | $33.95 | $37.76 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | 54.3K | ★ 363.6K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.22 | N/A |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $47.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.59 | $25.56 |
| 52 Week High | $37.41 | $37.83 |
| Indicator | VTMX | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 65.69 |
| Support Level | $33.54 | $26.42 |
| Resistance Level | $35.10 | N/A |
| Average True Range (ATR) | 0.66 | 2.40 |
| MACD | -0.02 | 0.22 |
| Stochastic Oscillator | 28.57 | 93.64 |
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.